BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1025 related articles for article (PubMed ID: 25443346)

  • 1. Natural history of hepatitis C.
    Westbrook RH; Dusheiko G
    J Hepatol; 2014 Nov; 61(1 Suppl):S58-68. PubMed ID: 25443346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
    Leone N; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):31-46. PubMed ID: 15756144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India.
    Kumar M; Kumar R; Hissar SS; Saraswat MK; Sharma BC; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2007 Jul; 22(7):1104-11. PubMed ID: 17559381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of hepatitis C and the impact of anti-viral therapy.
    Boyer N; Marcellin P
    Forum (Genova); 2000; 10(1):4-18. PubMed ID: 10717254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural history of hepatitis C.
    Seeff LB
    Hepatology; 1997 Sep; 26(3 Suppl 1):21S-28S. PubMed ID: 9305659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.
    Chen DS
    Princess Takamatsu Symp; 1995; 25():27-32. PubMed ID: 8875606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma and hepatitis C in the United States.
    El-Serag HB
    Hepatology; 2002 Nov; 36(5 Suppl 1):S74-83. PubMed ID: 12407579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma.
    Hsu YC; Wu CY; Lin JT
    Semin Oncol; 2015 Apr; 42(2):329-38. PubMed ID: 25843737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of hepatitis C virus infection in Korea.
    Suh DJ; Jeong SH
    Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
    Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
    Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
    J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
    Ueno Y; Sollano JD; Farrell GC
    J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of hepatitis C virus infection and liver cancer.
    Lim EJ; Torresi J
    Recent Results Cancer Res; 2014; 193():113-33. PubMed ID: 24008296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States.
    Hu KQ; Tong MJ
    Hepatology; 1999 Apr; 29(4):1311-6. PubMed ID: 10094980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.